Transdermal Drug Delivery Articles
-
Conducting A Medical Device Stability Study: A Practical Guide
1/7/2026
Stability studies measure how medical devices respond to environmental stresses such as temperature, humidity, light, and time. Let's take a closer look at designing and conducting a stability study.
-
Nanotechnology Drug Delivery: A Market Overview
1/6/2026
New market research reveals the scientific, geopolitical, and business trends driving growth in the nanotechnology drug delivery market.
-
Combination: The Drug Delivery Word Of The Year For 2026
12/30/2025
In this article, Chief Editor Tom von Gunden explains why he sees 2026 as the year combination products and therapies become fully central to drug and biologics product development, delivery, and regulatory. He points to personalized medicine and patient self-administration as key factors shaping his view of the drug delivery landscape.
-
Electronic Drug Delivery Devices Market: Advancing Smart, Connected Healthcare
12/19/2025
What is factoring into market growth for electronic drug delivery devices and why? New market research shares key insights.
-
Regulating For Patient Safety And Success With Combination Products
12/16/2025
At the AFDO/RAPS Combination Products Summit 2025, a notable focus emerged around approaches to risk assessment and human factors studies. In this article, Chief Editor Tom von Gunden offers his appreciation for the biopharma industry’s consideration of patient usability and safety in the development and regulation of combination products and other drug delivery devices.
-
Drug Delivery Trends From 2025: Top 4 For Momentum Gains In 2026
12/2/2025
In this article, Fran DeGrazio identifies four notable trends in drug delivery that gained momentum in 2025 and, she predicts, will continue to do so in 2026 and beyond. They are digitalization, sustainability, patient centricity, and the advanced delivery of complex biopharmaceuticals.
-
Drug Delivery Innovation: Getting Advanced Therapies To Patients
11/3/2025
In this article, Fran DeGrazio recounts the evolution of drug delivery technologies as she underscores the need to innovate in the delivery of advanced therapies. Considering chronic diseases, rare diseases, and difficult-to-reach therapeutic targets, Fran offers suggestions for organizing and readying for the development and delivery of platforms, systems, and devices for next generation treatments, including personalized, precision medicines.
-
Drug Delivery Product Strategy: Aligning The Organization For Execution
10/1/2025
In this article, Fran DeGrazio offers recommendations to biopharmaceutical sponsor companies about best practices for aligning strategic product initiatives with functional area execution. She outlines 5 key considerations, illustrated with the increasingly common market strategy expansion from drug product development to drug-device combination product delivery.
-
EU MDR: When Products Without An Intended Medical Purpose Meet Medicinal Substances
9/24/2025
One major change introduced by the EU MDR compared to the former European directives is the inclusion of products without an intended medical purpose but with similar risk profiles to medical devices, such as dermal fillers.
-
7 Management Strategies For Combination Product Regulatory Success
9/2/2025
In this article, Fran DeGrazio lays out best practices for biopharma executive leadership and non-technical managers to sustain regulatory momentum for their combination product development and commercialization. Fran points to cross-functional collaboration, quality management systems, regulatory documentation, and post-market surveillance as keys to drug delivery product success.